{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:44:55Z","timestamp":1778859895449,"version":"3.51.4"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1987,2,1]],"date-time":"1987-02-01T00:00:00Z","timestamp":539136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Toxicology"],"published-print":{"date-parts":[[1987,2]]},"DOI":"10.1007\/bf03259858","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T10:25:11Z","timestamp":1354184711000},"page":"10-32","source":"Crossref","is-referenced-by-count":51,"title":["Adverse Effects of Hypolipidaemic Drugs"],"prefix":"10.1007","volume":"2","author":[{"given":"Leroy C.","family":"Knodel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Talbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,27]]},"reference":[{"key":"BF03259858_CR1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1753-4887.1984.tb02278.x","volume":"42","author":"L Alhadeff","year":"1984","unstructured":"Alhadeff L, Gualtieri CT, Lipton M. Toxic effects of water-soluble vitamins. Nutrition Reviews 42: 33\u201340, 1984","journal-title":"Nutrition Reviews"},{"key":"BF03259858_CR2","first-page":"827","volume":"30","author":"DL Azarnoff","year":"1971","unstructured":"Azarnoff DL. Pharmacology of hypolipidemic drugs: introduction. Federation Proceedings 30: 827\u2013828, 1971","journal-title":"Federation Proceedings"},{"issue":"IV","key":"BF03259858_CR3","first-page":"123","volume":"64","author":"M Barber","year":"1981","unstructured":"Barber M, Mueller T, Gilmour Jr RF, Ziper DP. Electrophysiologic effects of probucol on monkey ventricle. (Abstract.) Circulation 64 (Suppl. IV): 123, 1981","journal-title":"Circulation"},{"key":"BF03259858_CR4","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jama.1972.03200060054009","volume":"220","author":"G Bazzano","year":"1972","unstructured":"Bazzano G, Bazzano GD. Digitalis intoxication: treatment with a new steroid-binding resin. Journal of the American Medical Association 220: 828\u2013830, 1972","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/000331976902001001","volume":"20","author":"LD Bechtol","year":"1969","unstructured":"Bechtol LD, Warner WL. Dextrothyroxine for lowering serum cholesterol. Angiology 20: 565\u2013579, 1969","journal-title":"Angiology"},{"key":"BF03259858_CR6","doi-asserted-by":"crossref","unstructured":"Bencze WL. Hypolipidemic agents. In Kritchevsky (Ed.) Hypolipidemic agents, p. 349, Springer, Berlin, 1975","DOI":"10.1007\/978-3-642-66190-7_9"},{"key":"BF03259858_CR7","first-page":"1220","volume":"132","author":"B Bernstein","year":"1978","unstructured":"Bernstein B, Zoger S. Hyperchloremic metabolic acidosis with cholestyramine therapy for biliary cholestasis. Correspondence. American Journal of Diseases of Children 132: 1220, 1978","journal-title":"Correspondence. American Journal of Diseases of Children"},{"key":"BF03259858_CR8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-3565(25)31754-4","volume":"210","author":"TD Bjornsson","year":"1979","unstructured":"Bjornsson TD, Meffin PJ, Swezey S, Blaschke TF. Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. Journal of Pharmacology and Experimental Therapeutics 210: 316\u2013321, 1979","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"BF03259858_CR9","first-page":"139","volume":"117","author":"J Bommer","year":"1975","unstructured":"Bommer J, Speders H, Ehrke V. Treatment of hypercholesterolemia after myocardial infarction with D-thyroxine. Munchener Medizinische Wochenschrift 117: 139\u2013142, 1975","journal-title":"Munchener Medizinische Wochenschrift"},{"key":"BF03259858_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.CIR.69.2.313","volume":"69","author":"JF Brensike","year":"1984","unstructured":"Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation 69: 313\u2013324, 1984","journal-title":"Circulation"},{"key":"BF03259858_CR11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0140-6736(72)91905-8","volume":"2","author":"CJF Bridgeman","year":"1972","unstructured":"Bridgeman CJF, Rosen SM, Thorp JM. Complications during clofibrate treatment of nephrotic syndrome hyperlipoproteinaemia. Lancet 2: 506\u2013509, 1972","journal-title":"Lancet"},{"key":"BF03259858_CR12","first-page":"827","volume-title":"The pharmacological basis of therapeutics","author":"MS Brown","year":"1985","unstructured":"Brown MS, Goldstein JL. Drugs used in the treatment of hyperlipoproteinemias. In Goodman et al. (Eds) The pharmacological basis of therapeutics, 7th ed., pp. 827\u2013845, McMillan Publishing Co., New York, 1985","edition":"7th"},{"key":"BF03259858_CR13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/0002-8703(84)90315-6","volume":"107","author":"KF Browne","year":"1984","unstructured":"Browne KF, Prystowsky EN, Heger JJ, Cerimele BJ, Fineberg N, et al. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug. American Heart Journal 107: 680\u2013684, 1984","journal-title":"American Heart Journal"},{"key":"BF03259858_CR14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1210\/jcem-30-6-733","volume":"30","author":"K Brown-Grant","year":"1970","unstructured":"Brown-Grant K, Brennan RD, Yates FE. Simulation of thyroid hormone-binding interactions in human plasma. Journal of Clinical Endocrinology and Metabolism 30: 733\u2013751, 1970","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"BF03259858_CR15","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1172\/JCI106764","volume":"50","author":"JH Caldwell","year":"1971","unstructured":"Caldwell JH, Bush CA, Greenberger NJ. Interruption of the enterohepatic circulation of digitoxin by cholestyramine. Journal of Clinical Investigation 50: 2638\u20132644, 1971","journal-title":"Journal of Clinical Investigation"},{"key":"BF03259858_CR16","first-page":"166","volume":"147","author":"TJ Cali","year":"1975","unstructured":"Cali TJ. Combined therapy with cholestyramine and warfarin. American Journal of Pharmacy 147: 166\u2013169, 1975","journal-title":"American Journal of Pharmacy"},{"key":"BF03259858_CR17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/clpt.1980.28","volume":"27","author":"SG Carruthers","year":"1980","unstructured":"Carruthers SG, Dujovne CA. Cholestyramine and spironolactone and their combination in digitoxin elimination. Clinical Pharmacology and Therapeutics 27: 184\u2013187, 1980","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259858_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF03259840","volume":"1","author":"JL Carson","year":"1986","unstructured":"Carson JL, Strom BL. Techniques of postmarketing surveillance: an overview. Medical Toxicology 1: 237\u2013246, 1986","journal-title":"Medical Toxicology"},{"key":"BF03259858_CR19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/0003-4819-74-5-818_2","volume":"74","author":"HR Casdorph","year":"1971","unstructured":"Casdorph HR. The efficacy and safety of cholestyramine therapy in hyperlipidemic patients. (Abstract.) Annals of Internal Medicine 74: 818, 1971","journal-title":"(Abstract.) Annals of Internal Medicine"},{"key":"BF03259858_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/000331977202300105","volume":"23","author":"RC Charman","year":"1972","unstructured":"Charman RC, Mathews LB, Braeuler C. Nicotinic acid in the treatment of hypercholesterolemia. Angiology 23: 29\u201335, 1972","journal-title":"Angiology"},{"key":"BF03259858_CR21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jama.1961.03040340010003","volume":"177","author":"NA Christensen","year":"1961","unstructured":"Christensen NA, Achor RWP, Berge KG, Mason HL. Nicotinic acid treatment of hypercholesterolemia. Journal of the American Medical Association 177: 546\u2013550, 1961","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00007611-197702000-00046","volume":"70","author":"RW Cihak","year":"1977","unstructured":"Cihak RW, Beary FD. Elevated triiodothyronine and dextrothyroxine levels: a potential cause of iatrogenic hyperthyroidism. Southern Medical Journal 70: 256\u2013257, 1977","journal-title":"Southern Medical Journal"},{"key":"BF03259858_CR23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1445-5994.1985.tb04032.x","volume":"15","author":"WM Clouston","year":"1985","unstructured":"Clouston WM, Lloyd HM. Cholestyramine induced hyperchloremic metabolic acidosis. Correspondence. Australian and New Zealand Journal of Medicine 15: 271, 1985","journal-title":"Correspondence. Australian and New Zealand Journal of Medicine"},{"key":"BF03259858_CR24","first-page":"45","volume":"9","author":"BM Cohen","year":"1969","unstructured":"Cohen BM. The clinical use of dextrothyroxine in hypercholesterolemic states: an eight-year appraisal. Journal of Clinical Pharmacology 9: 45\u201356, 1969","journal-title":"Journal of Clinical Pharmacology"},{"key":"BF03259858_CR25","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM196906052802307","volume":"280","author":"MI Cohen","year":"1969","unstructured":"Cohen MI, Winslow PR, Boley SJ. Intestinal obstruction associated with cholestyramine therapy. New England Journal of Medicine 280: 1285\u20131286, 1969","journal-title":"New England Journal of Medicine"},{"key":"BF03259858_CR26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","volume":"40","author":"Committee of Principal Investigators WHO.","year":"1978","unstructured":"Committee of Principal Investigators (WHO).A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. British Heart Journal 40: 1069\u20131118, 1978","journal-title":"British Heart Journal"},{"key":"BF03259858_CR27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/0016-5085(78)90150-6","volume":"74","author":"JE Compston","year":"1978","unstructured":"Compston JE, Horton LWL. Oral 25-hydroxyvitamin D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. Gastroenterology 74: 900\u2013902, 1978","journal-title":"Gastroenterology"},{"key":"BF03259858_CR28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(77)92167-5","volume":"1","author":"JE Compston","year":"1977","unstructured":"Compston JE, Thompson RPH. Intestinal absorption of 25-hydroxy-vitamin D and osteomalacia in primary biliary cirrhosis. Lancet 1: 721\u2013724, 1977","journal-title":"Lancet"},{"key":"BF03259858_CR29","first-page":"191","volume":"82","author":"EE Cooper","year":"1977","unstructured":"Cooper EE, Michel AM. Colestipol hydrochloride, a new hypolipidemic drug: a two-year study \u2014 summary. Advances in Experimental Medicine and Biology 82: 191\u2013194, 1977","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"BF03259858_CR30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","volume":"231","author":"Coronary Drug Project Research Group.","year":"1975","unstructured":"Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. Journal of the American Medical Association 231: 360\u2013381, 1975","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR31","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jama.1972.03200070084015","volume":"220","author":"Coronary Drug Project Research Group.","year":"1972","unstructured":"Coronary Drug Project Research Group. The coronary drug project: findings leading to further modifications of its protocol with respect to dextrothyroxine. Journal of the American Medical Association 220: 996\u20131008, 1972","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR32","first-page":"224","volume":"7","author":"G Dahlen","year":"1980","unstructured":"Dahlen G, Gillnas T, Borresen AL, Berg K, Ericson C. Effect of gemfibrozil on serum lipid levels. Artery 7: 224\u2013231, 1980","journal-title":"Artery"},{"key":"BF03259858_CR33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2125.1979.tb04649.x","volume":"7","author":"JC Daubresse","year":"1979","unstructured":"Daubresse JC, Daigneux JC, Bruwier M, Luyckx A, Lefebvre PJ. Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents. British Journal of Clinical Pharmacology 7: 599\u2013603, 1979","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259858_CR34","first-page":"613","volume":"294","author":"JC Daubresse","year":"1976","unstructured":"Daubresse JC, Luyckx AS, Lefebvre PJ. Potentiation of hypoglycemic effect of sulfonylureas by clofibrate. Correspondence. New England Journal of Medicine 294: 613, 1976","journal-title":"Correspondence. New England Journal of Medicine"},{"key":"BF03259858_CR35","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0016-5085(68)80140-4","volume":"54","author":"WO Dobbins","year":"1968","unstructured":"Dobbins WO. Drug-induced steatorrhea. Gastroenterology 54: 1193\u20131195, 1968","journal-title":"Gastroenterology"},{"key":"BF03259858_CR36","first-page":"316","volume":"60","author":"PR Donald","year":"1981","unstructured":"Donald PR, Sellars SL. Streptomycin ototoxicity in the unborn child. South African Medical Journal 60: 316\u2013318, 1981","journal-title":"South African Medical Journal"},{"key":"BF03259858_CR37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/bmj.3.5871.86","volume":"3","author":"B Dordoni","year":"1973","unstructured":"Dordoni B, Willson RA, Thompson RPH, Williams R. Reduction of absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure. British Medical Journal 3: 86\u201387, 1973","journal-title":"British Medical Journal"},{"key":"BF03259858_CR38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0021-9681(78)90076-0","volume":"31","author":"AE Dorr","year":"1978","unstructured":"Dorr AE, Gundersen K, Schneider Jr JC, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients \u2014 effect on serum cholesterol and mortality. Journal of Chronic Diseases 31: 5\u201314, 1978","journal-title":"Journal of Chronic Diseases"},{"key":"BF03259858_CR39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF00541934","volume":"26","author":"CA Dujovne","year":"1984","unstructured":"Dujovne CA, Atkins F, Wong B, DeCoursey S, Krehbiel P, et al. Electrocardiographic effects of probucol: a controlled prospective clinical trial. European Journal of Clinical Pharmacology 26: 735\u2013739, 1984c","journal-title":"European Journal of Clinical Pharmacology"},{"key":"BF03259858_CR40","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/0002-9149(84)90570-8","volume":"53","author":"CA Dujovne","year":"1984","unstructured":"Dujovne CA, Chernoff SB, Krehbiel P, Jackson B, DeCoursey S, et al. Low-dose colestipol plus probucol for hypercholesterolemia. American Journal of Cardiology 53: 1514\u20131518, 1984b","journal-title":"American Journal of Cardiology"},{"key":"BF03259858_CR41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-100-4-477","volume":"100","author":"CA Dujovne","year":"1984","unstructured":"Dujovne CA, Krehbiel P, DeCoursey S, Jackson B, Chernoff SB, et al. Probucol with colestipol in the treatment of hypercholesterolemia. Annals of Internal Medicine 100: 477\u2013482, 1984a","journal-title":"Annals of Internal Medicine"},{"key":"BF03259858_CR42","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0140-6736(73)91782-0","volume":"1","author":"RD Eastham","year":"1973","unstructured":"Eastham RD. Warfarin dosage influenced by clofibrate plus age. Correspondence. Lancet 1: 1450, 1973","journal-title":"Correspondence. Lancet"},{"key":"BF03259858_CR43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1445-5994.1984.tb05023.x","volume":"14","author":"ER Eaves","year":"1984","unstructured":"Eaves ER, Korman MG. Cholestyramine induced hyperchloremic metabolic acidosis. Australian and New Zealand Journal of Medicine 14: 670\u2013672, 1984","journal-title":"Australian and New Zealand Journal of Medicine"},{"issue":"2","key":"BF03259858_CR44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/00359157760690S213","volume":"69","author":"A Eisalo","year":"1976","unstructured":"Eisalo A, Manninen V. A long-term trial of gemfibrozil in the treatment of hyperlipidaemias. Proceedings of the Royal Society of Medicine 69 (Suppl. 2): 49\u201352, 1976","journal-title":"Proceedings of the Royal Society of Medicine"},{"key":"BF03259858_CR45","first-page":"711","volume":"17","author":"H Engelberg","year":"1962","unstructured":"Engelberg H. Effect of sodium D-thyroxine on serum cholesterol and low-density lipoproteins in man. Geriatrics 17: 711\u2013714, 1962","journal-title":"Geriatrics"},{"key":"BF03259858_CR46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/00016347009157511","volume":"49","author":"J Engstrom","year":"1970","unstructured":"Engstrom J, Hellstrom K, Posse N, Sjovall J. Recurrent cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavica 49: 29\u201334, 1970","journal-title":"Acta Obstetricia et Gynecologica Scandinavica"},{"key":"BF03259858_CR47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0021-9150(75)90023-4","volume":"22","author":"R Fellin","year":"1975","unstructured":"Fellin R, Briani G, Balestrieri P, Baggio G, Baiocchi MR, et al. Long-term effects of colestipol (U-26,597 A) on plasma lipids in familial type II hyperbetalipoproteinaemia. Atherosclerosis 22: 431\u2013445, 1975","journal-title":"Atherosclerosis"},{"key":"BF03259858_CR48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0021-9150(86)90032-8","volume":"59","author":"R Fellin","year":"1986","unstructured":"Fellin R, Gasparotto A, Valerio G, Baiocchi MR, Padrini R, et al. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolaemia. Atherosclerosis 59: 47\u201356, 1986","journal-title":"Atherosclerosis"},{"key":"BF03259858_CR49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/000331978203300904","volume":"33","author":"RW Fenderson","year":"1982","unstructured":"Fenderson RW, Deutsch S, Menachemi E, Chin B, Samuel P. Effect of gemfibrozil on serum lipids in man. Angiology 33: 581\u2013593, 1982","journal-title":"Angiology"},{"key":"BF03259858_CR50","first-page":"1105","volume":"67","author":"JE Fitzgerald","year":"1981","unstructured":"Fitzgerald JE, Sanyer JL, Schardein JL, Lake RS, et al. Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil. Journal of the National Cancer Institute 67: 1105\u20131116, 1981","journal-title":"Journal of the National Cancer Institute"},{"key":"BF03259858_CR51","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5694\/j.1326-5377.1976.tb130077.x","volume":"2","author":"JM Forrest","year":"1976","unstructured":"Forrest JM. Drugs in pregnancy and lactation. Medical Journal of Australia 2: 138\u2013141, 1976","journal-title":"Medical Journal of Australia"},{"key":"BF03259858_CR52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3181\/00379727-120-30443","volume":"120","author":"DG Gallo","year":"1965","unstructured":"Gallo DG, Bailey KR, Sheffner AJ. The interaction between cholestyramine and drugs. Proceedings of the Society for Experimental Biology and Medicine 120: 60\u201365, 1965","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"BF03259858_CR53","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0002-9394(73)90738-1","volume":"76","author":"JDM Gass","year":"1973","unstructured":"Gass JDM. Nicotinic acid maculopathy. American Journal of Ophthalmology 76: 500\u2013510, 1973","journal-title":"American Journal of Ophthalmology"},{"key":"BF03259858_CR54","doi-asserted-by":"crossref","first-page":"475","DOI":"10.7326\/0003-4819-96-4-475","volume":"96","author":"CJ Glueck","year":"1982","unstructured":"Glueck CJ. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. Annals of Internal Medicine 96: 475\u2013482, 1982","journal-title":"Annals of Internal Medicine"},{"key":"BF03259858_CR55","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.1972.03210060032007","volume":"222","author":"CJ Glueck","year":"1972","unstructured":"Glueck CJ, Ford Jr S, School D, Steiner P. Colestipol and cholestyramine resin: comparative effects in familial type II hyperlipoproteinemia. Journal of the American Medical Association 222: 676\u2013681, 1972","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/cpt1977213317","volume":"21","author":"AP Goldberg","year":"1977","unstructured":"Goldberg AP. Sherrard DJ, Hass LB, Brunzell JD. Control of clofibrate toxicity in uremic hypertriglyceridemia. Clinical Pharmacology and Therapeutics 21: 317\u2013325, 1977","journal-title":"Control of clofibrate toxicity in uremic hypertriglyceridemia. Clinical Pharmacology and Therapeutics"},{"key":"BF03259858_CR57","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/0002-9343(79)90649-1","volume":"67","author":"PHR Green","year":"1979","unstructured":"Green PHR, Tall AR. Drugs, alcohol and malabsorption. American Journal of Medicine 67: 1066\u20131076, 1979","journal-title":"American Journal of Medicine"},{"key":"BF03259858_CR58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-89-2-234","volume":"89","author":"P Greenberger","year":"1978","unstructured":"Greenberger P, Patterson R. Safety of therapy for allergic symptoms during pregnancy. Annals of Internal Medicine 89: 234\u2013237, 1978","journal-title":"Annals of Internal Medicine"},{"key":"BF03259858_CR59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-72-1-95","volume":"72","author":"L Gross","year":"1970","unstructured":"Gross L, Brotman M. Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy. Annals of Internal Medicine 72: 95\u201396, 1970","journal-title":"Annals of Internal Medicine"},{"key":"BF03259858_CR60","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-197803060-00001","volume":"3","author":"R Gugler","year":"1978","unstructured":"Gugler R. Clinical pharmacokinetics of hypolipidaemic drugs. Clinical Pharmacokinetics 3: 425\u2013439, 1978","journal-title":"Clinical Pharmacokinetics"},{"key":"BF03259858_CR61","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1172\/JCI108035","volume":"55","author":"R Gugler","year":"1975","unstructured":"Gugler R, Shoeman DW, Huffman DH, Cohlmia JB, Azarnoff DL. Pharmacokinetics of drugs in patients with the nephrotic syndrome. Journal of Clinical Investigation 55: 1182\u20131189, 1975","journal-title":"Journal of Clinical Investigation"},{"key":"BF03259858_CR62","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0021-9150(81)90008-3","volume":"39","author":"MJ Hall","year":"1981","unstructured":"Hall MJ, Nelson LM, Rusell RI, Howard AN. Gemfibrozil: the effect on biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate. Atherosclerosis 39: 511\u2013516, 1981","journal-title":"Atherosclerosis"},{"key":"BF03259858_CR63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0002-9149(77)80193-8","volume":"39","author":"WH Hall","year":"1977","unstructured":"Hall WH, Shapell SD, Doherty JE. Effect of cholestyramine on digoxin absorption and excretion in man. American Journal of Cardiology 39: 213\u2013216, 1977","journal-title":"American Journal of Cardiology"},{"key":"BF03259858_CR64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00003072-198401000-00007","volume":"9","author":"JH Hankins","year":"1984","unstructured":"Hankins JH, Heise CM, Cowman RJ. Iatrogenic hyperthyroidism secondary to dextrothyroxine administration. Clinical Nuclear Medicine 9: 17\u201319, 1984","journal-title":"Clinical Nuclear Medicine"},{"key":"BF03259858_CR65","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0002-9394(63)91658-1","volume":"55","author":"JL Harris","year":"1963","unstructured":"Harris JL. Toxic amblyopia associated with administration of nicotinic acid. American Journal of Ophthamology 55: 133\u2013134, 1963","journal-title":"American Journal of Ophthamology"},{"key":"BF03259858_CR66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1532-5415.1974.tb02163.x","volume":"22","author":"RS Harris","year":"1974","unstructured":"Harris RS, Gilmore HR, Bricker LA, Kiem IM, Rubin E. Long-term oral administration of probucol [4,4\u2032-(isopropylidenedithio) bis (2,6-di-t-butylphenol)] (DH-581) in the management of hypercholesterolemia. Journal of the American Geriatrics Society 22: 167\u2013175, 1974","journal-title":"Journal of the American Geriatrics Society"},{"key":"BF03259858_CR67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-3476(76)80958-4","volume":"89","author":"JV Hartline","year":"1976","unstructured":"Hartline JV. Hyperchloremic, metabolic acidosis, and cholestyramine. Correspondence. Journal of Pediatrics 89: 155, 1976","journal-title":"Correspondence. Journal of Pediatrics"},{"key":"BF03259858_CR68","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt1976203310","volume":"20","author":"C Harvengt","year":"1976","unstructured":"Harvengt C, Desager J-P. Colestipol in familial type II hyperlipoproteinemia: a three-year trial. Clinical Pharmacology and Therapeutics 20: 310\u2013314, 1976","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259858_CR69","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0016-5085(72)80051-9","volume":"62","author":"KW Heaton","year":"1972","unstructured":"Heaton KW, Lever JV, Barnard D. Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea. Gastroenterology 62: 642\u2013646, 1972","journal-title":"Gastroenterology"},{"key":"BF03259858_CR70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003495-198019030-00001","volume":"19","author":"RC Heel","year":"1980","unstructured":"Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia. Drugs 19: 161\u2013180, 1980","journal-title":"Drugs"},{"key":"BF03259858_CR71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00003495-197815060-00001","volume":"15","author":"RC Heel","year":"1978","unstructured":"Heel RC, Brogden RN, Speight TM, Avery GS. Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia. Drugs 15: 409\u2013428, 1978","journal-title":"Drugs"},{"key":"BF03259858_CR72","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/0002-9149(85)90489-8","volume":"55","author":"JA Hoeg","year":"1985","unstructured":"Hoeg JA, Maher MB, Bailey KR, Zech LA, Gregg RE, et al. Effects of combination cholestyramine-neomycin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. American Journal of Cardiology 55: 1282\u20131286, 1985","journal-title":"American Journal of Cardiology"},{"key":"BF03259858_CR73","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/01.CIR.70.6.1004","volume":"70","author":"JM Hoeg","year":"1984","unstructured":"Hoeg JM, Maher MB, Bou E, Zech LA, Bailey KR, et al. Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin. Circulation 70: 1004\u20131011, 1984a","journal-title":"Circulation"},{"key":"BF03259858_CR74","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/clpt.1984.219","volume":"36","author":"JM Hoeg","year":"1984","unstructured":"Hoeg JM, Schaefer EJ, Romano CA, Bou E, Pikus AM, et al. Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. Clinical Pharmacology and Therapeutics 36: 555\u2013565, 1984b","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259858_CR75","first-page":"195","volume":"20","author":"W Hotz","year":"1983","unstructured":"Hotz W. Nicotinic acid and its derivatives: a short survey. Advances in Lipid Research 20: 195\u2013217, 1983","journal-title":"Advances in Lipid Research"},{"key":"BF03259858_CR76","first-page":"150","volume":"16","author":"G Houin","year":"1978","unstructured":"Houin G, Tillement JP. Clofibrate and enzymatic induction in man. International Journal of Clinical Pharmacology 16: 150\u2013154, 1978","journal-title":"International Journal of Clinical Pharmacology"},{"key":"BF03259858_CR77","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.1973.03230110046018","volume":"226","author":"EJ Howard","year":"1973","unstructured":"Howard EJ, Brown SM. Clofibrate-induced antinuclear factor and lupus-like syndrome. Journal of the American Medical Association 226: 1358\u20131359, 1973","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR78","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0021-9150(80)90153-7","volume":"37","author":"DB Hunninghake","year":"1980","unstructured":"Hunninghake DB, Bell G, Olson L. Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia. Atherosclerosis 37: 469\u2013474, 1980","journal-title":"Atherosclerosis"},{"key":"BF03259858_CR79","first-page":"220","volume":"20","author":"DB Hunninghake","year":"1978","unstructured":"Hunninghake DB, King S. Effect of cholestyramine and colestipol on the absorption of methyldopa and hydrochlorothiazide. (Abstract.) Pharmacologist 20: 220, 1978","journal-title":"(Abstract.) Pharmacologist"},{"key":"BF03259858_CR80","first-page":"151","volume":"20","author":"DB Hunninghake","year":"1982","unstructured":"Hunninghake DB, King S, LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. International Journal of Clinical Pharmacology, Therapeutics and Toxicology 20: 151\u2013154, 1982","journal-title":"International Journal of Clinical Pharmacology, Therapeutics and Toxicology"},{"key":"BF03259858_CR81","first-page":"996","volume":"36","author":"DB Hunninghake","year":"1977","unstructured":"Hunninghake DB, Pollack E. Effect of bile acid sequestering agents on the absorption of aspirin, tolbutamide and warfarin. (Abstract.) Federation Proceedings 36: 996, 1977","journal-title":"(Abstract.) Federation Proceedings"},{"key":"BF03259858_CR82","first-page":"613","volume":"294","author":"AK Jain","year":"1976","unstructured":"Jain AK, Ryan JR, McMahon FG. Potentiation of hypoglycemic effect of sulfonylureas by clofibrate. Correspondence. New England Journal of Medicine 294: 613, 1976","journal-title":"Correspondence. New England Journal of Medicine"},{"key":"BF03259858_CR83","first-page":"752","volume":"111","author":"EM Janke","year":"1974","unstructured":"Janke EM. Reaction to clofibrate. Correspondence. Canadian Medical Association Journal 111: 752, 1974","journal-title":"Correspondence. Canadian Medical Association Journal"},{"key":"BF03259858_CR84","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.0954-6820.1978.tb08481.x","volume":"204","author":"C Johansson","year":"1978","unstructured":"Johansson C, Adamsson U, Stierner U, Lindsten T. Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract. Acta Medica Scandinavica 204: 509\u2013512, 1978","journal-title":"Acta Medica Scandinavica"},{"key":"BF03259858_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(84)90099-6","volume":"53","author":"DB Jones","year":"1984","unstructured":"Jones DB, Simpson HCR, Slaughter P, Lousley S, Carter RD, et al. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia. Atherosclerosis 53: 1\u20137, 1984","journal-title":"Atherosclerosis"},{"key":"BF03259858_CR86","first-page":"201","volume":"65","author":"HC Jones","year":"1973","unstructured":"Jones HC. Intrauterine ototoxicity: a case report and review of the literature. Journal of the National Medical Association 65: 201\u2013203, 1973","journal-title":"Journal of the National Medical Association"},{"key":"BF03259858_CR87","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJM198101293040502","volume":"304","author":"JP Kane","year":"1981","unstructured":"Kane JP, Malloy MJ, Tun P, Phillips NR, Freedman DD, et al. Normalization of low-density lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. New England Journal of Medicine 304: 251\u2013258, 1981","journal-title":"New England Journal of Medicine"},{"key":"BF03259858_CR88","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt1973145886","volume":"14","author":"RE Kauffman","year":"1973","unstructured":"Kauffman RE, Azarnoff DL. Effect of colestipol on gastrointestinal absorption of chlorothiazide in man. Clinical Pharmacology and Therapeutics 14: 886\u2013890, 1973","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259858_CR89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.0954-6820.1981.tb11554.x","volume":"209","author":"S Kaukola","year":"1981","unstructured":"Kaukola S, Manninen V, Malkonen A, Ehnholm C. Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. Acta Medica Scandinavica 209: 69\u201373, 1981","journal-title":"Acta Medica Scandinavica"},{"key":"BF03259858_CR90","first-page":"861","volume":"290","author":"PK Kleinman","year":"1974","unstructured":"Kleinman PK. Cholestyramine and metabolic acidosis. Correspondence. New England Journal of Medicine 290: 861, 1974","journal-title":"Correspondence. New England Journal of Medicine"},{"key":"BF03259858_CR91","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/s-0028-1107788","volume":"99","author":"UH Klemens","year":"1974","unstructured":"Klemens UH, von Lowis of Menar P. Therapy of hyperlipoproteinemia of types IIa and IIb with highly purified D-thyroxine (D-T4): a controlled study in outpatients. Deutsche Medizinische Wochenschrift 99: 487\u2013493, 1974","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"BF03259858_CR92","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","volume":"34","author":"RH Knopp","year":"1985","unstructured":"Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to the mechanism of action of niacin. Metabolism 34: 642\u2013650, 1985","journal-title":"Metabolism"},{"key":"BF03259858_CR93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00000441-196908000-00005","volume":"258","author":"RM Kohn","year":"1969","unstructured":"Kohn RM, Montes M. Hepatic fibrosis following long acting nicotinic acid therapy. American Journal of the Medical Sciences 258: 94\u201399, 1969","journal-title":"American Journal of the Medical Sciences"},{"key":"BF03259858_CR94","first-page":"240","volume":"11","author":"A Konttinen","year":"1979","unstructured":"Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K. The effect of gemfibrozil on serum lipids in diabetic patients. Annals of Clinical Research 11: 240\u2013245, 1979","journal-title":"Annals of Clinical Research"},{"key":"BF03259858_CR95","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0028-1107789","volume":"99","author":"T Koschinsky","year":"1974","unstructured":"Koschinsky T, Vogelberg KH, Gries FA. Therapy of primary hyperlipoproteinemia type IIa and IIb with D-thyroxine. Deutsche Medizinische Wochenschrift 99: 494\u2013496, 1974","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"BF03259858_CR96","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0140-6736(71)91440-1","volume":"1","author":"DM Krikler","year":"1971","unstructured":"Krikler DM, Lefevre D, Lewis B. Dextrothyroxine with propranolol in the treatment of hypercholesterolaemia. Lancet 1: 934\u2013936, 1971","journal-title":"Lancet"},{"key":"BF03259858_CR97","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/01.CIR.59.2.199","volume":"59","author":"PT Kuo","year":"1979","unstructured":"Kuo PT, Hayase K, Kostis JB, Moreyra AE. Use of combined diet and colestipol in long-term (7\u201371\/2 years) treatment of patients with type II hyperlipoproteinemia. Circulation 59: 199\u2013211, 1979","journal-title":"Circulation"},{"key":"BF03259858_CR98","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJM196810172791604","volume":"279","author":"T Langer","year":"1978","unstructured":"Langer T, Levy RI. Acute muscular syndrome associated with the administration of clofibrate. New England Journal of Medicine 279: 856\u2013858, 1978","journal-title":"New England Journal of Medicine"},{"key":"BF03259858_CR99","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0002-9149(69)90076-9","volume":"23","author":"JC Rosa La","year":"1969","unstructured":"La Rosa JC, Brown WV, Frommer PL, Levy RI. Clofibrate-induced ventricular arrhythmia. American Journal of Cardiology 23: 266\u2013269, 1969","journal-title":"American Journal of Cardiology"},{"key":"BF03259858_CR100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0026-0495(85)90064-2","volume":"34","author":"O Leiss","year":"1985","unstructured":"Leiss O, von Bergmann K, Gnasso A, Augustin J. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects. Metabolism 34: 74\u201382, 1985","journal-title":"Metabolism"},{"key":"BF03259858_CR101","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2165\/00003495-198530050-00004","volume":"30","author":"MN Levine","year":"1985","unstructured":"Levine MN, Raskob G, Hirsh J. Risk of haemorrhage associated with long term anticoagulant therapy. Drugs 30: 444\u2013460, 1985","journal-title":"Drugs"},{"key":"BF03259858_CR102","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/000331978203300906","volume":"33","author":"JE Lewis","year":"1982","unstructured":"Lewis JE. Long-term use of gemfibrozil (Lopid\u00ae) in the treatment of dyslipidemia. Angiology 33: 603\u2013612, 1982","journal-title":"Angiology"},{"key":"BF03259858_CR103","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0016-5085(76)80443-X","volume":"71","author":"J Lindenbaum","year":"1976","unstructured":"Lindenbaum J, Maulitz RM, Butler Jr VP. Inhibition of digoxin absorption by neomycin. Gastroenterology 71: 399\u2013404, 1976","journal-title":"Gastroenterology"},{"key":"BF03259858_CR104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0002-9343(81)90260-6","volume":"71","author":"J Lindenbaum","year":"1981","unstructured":"Lindenbaum J, Tse-Eng D, Butler Jr VP, Rund DG. Urinary excretion of reduced metabolites of digoxin. American Journal of Medicine 71: 67\u201374, 1981","journal-title":"American Journal of Medicine"},{"key":"BF03259858_CR105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","volume":"251","author":"Lipid Research Clinics Program.","year":"1984","unstructured":"Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. Journal of the American Medical Association 251: 351\u2013364, 1984","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR106","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0021-9150(80)90003-9","volume":"37","author":"H Lithell","year":"1980","unstructured":"Lithell H, Vessby B, Boberg J, Hellsing K. The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Atherosclerosis 37: 175\u2013186, 1980","journal-title":"Atherosclerosis"},{"key":"BF03259858_CR107","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1542\/peds.59.4.626","volume":"59","author":"JD Lloyd-Still","year":"1977","unstructured":"Lloyd-Still JD. Cholestyramine therapy and intestinal obstruction in infants. Pediatrics 59: 626\u2013627, 1977","journal-title":"Pediatrics"},{"key":"BF03259858_CR108","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00006250-196901000-00011","volume":"33","author":"EE Lutz","year":"1969","unstructured":"Lutz EE, Margolis AJ. Obstetric hepatosis: treatment with cholestyramine and interim response to steroids. Obstetrics and Gynecology 33: 64\u201371, 1969","journal-title":"Obstetrics and Gynecology"},{"key":"BF03259858_CR109","first-page":"15","volume":"2","author":"MH MacGillivray","year":"1975","unstructured":"MacGillivray MH. Thyroid dysfunction in the neonatal period. Clinics in Perinatology 2: 15\u201321, 1975","journal-title":"Clinics in Perinatology"},{"key":"BF03259858_CR110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.0954-6820.1982.tb08526.x","volume":"668","author":"V Manninen","year":"1982","unstructured":"Manninen V, Malkonen M, Eisalo A, Virtamo J, Tuomilehto J, et al. Gemfibrozil in the treatment of dyslipidaemia: a 5-year follow-up study. Acta Medica Scandinavica 668 (Suppl.): 82\u201387, 1982","journal-title":"Acta Medica Scandinavica"},{"key":"BF03259858_CR111","first-page":"95","volume":"4","author":"J Marks","year":"1982","unstructured":"Marks J, Howard AN. A comparative study of gemfibrozil and clofibrate in the treatment of hyperlipidaemia in patients with maturity-onset diabetes. Research and Clinical Forums 4: 95\u2013103, 1982","journal-title":"Research and Clinical Forums"},{"key":"BF03259858_CR112","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0041-008X(73)90221-4","volume":"24","author":"FN Marshall","year":"1973","unstructured":"Marshall FN, Lewis JE. Sensitization to epinephrine-induced ventricular fibrillation induced by probucol in dogs. Toxicology and Applied Pharmacology 24: 594\u2013602, 1973","journal-title":"Toxicology and Applied Pharmacology"},{"key":"BF03259858_CR113","first-page":"423","volume":"4","author":"MS Matsui","year":"1982","unstructured":"Matsui MS, Rozovski SJ. Drug-nutrient interaction. Clinical Therapeutics 4: 423\u2013440, 1982","journal-title":"Clinical Therapeutics"},{"key":"BF03259858_CR114","first-page":"175","volume-title":"Diet and drugs in atherosclerosis","author":"D McCaughan","year":"1980","unstructured":"McCaughan D. Probucol in the long-term management of hypercholesterolemia. In Noseda et al. (Eds) Diet and drugs in atherosclerosis, pp. 175\u2013179, Raven Press, New York, 1980"},{"key":"BF03259858_CR115","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/archinte.1981.00340120036010","volume":"141","author":"D McCaughan","year":"1981","unstructured":"McCaughan D. The long-term effects of probucol on serum lipid levels. Archives of Internal Medicine 141: 1428\u20131432, 1981","journal-title":"Archives of Internal Medicine"},{"key":"BF03259858_CR116","first-page":"56","volume":"10","author":"D McCaughan","year":"1982","unstructured":"McCaughan D. Nine years of treatment with probucol. Artery 10: 56\u201370, 1982","journal-title":"Artery"},{"key":"BF03259858_CR117","first-page":"742","volume-title":"Drug Information 86","year":"1986","unstructured":"McEvoy GK, McQuarrie GM (Eds). Drug Information 86, p. 742, American Society of Hospital Pharmacists, Bethesda, 1986"},{"key":"BF03259858_CR118","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.1973.03220330050025","volume":"225","author":"JFX McGarvey","year":"1973","unstructured":"McGarvey JFX. Premature contractions and clofibrate. Correspondence. Journal of the American Medical Association 225: 638, 1973","journal-title":"Correspondence. Journal of the American Medical Association"},{"key":"BF03259858_CR119","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0026-0495(80)90039-6","volume":"29","author":"MJ Mellies","year":"1980","unstructured":"Mellies MJ, Gartside PS, Glatfelter L, Vink P, Guy G, et al. Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia. Metabolism 29: 956\u2013963, 1980","journal-title":"Metabolism"},{"key":"BF03259858_CR120","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2214\/ajr.134.4.827","volume":"134","author":"DF Merten","year":"1980","unstructured":"Merten DF, Grossman H. Intestinal obstruction associated with cholestyramine therapy. American Journal of Roentgenology 134: 827\u2013828, 1980","journal-title":"American Journal of Roentgenology"},{"key":"BF03259858_CR121","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1172\/JCI109607","volume":"64","author":"TA Miettinen","year":"1979","unstructured":"Miettinen TA. Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects. Journal of Clinical Investigation 64: 1485\u20131493, 1979","journal-title":"Journal of Clinical Investigation"},{"key":"BF03259858_CR122","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.5694\/j.1326-5377.1973.tb111068.x","volume":"1","author":"NE Miller","year":"1973","unstructured":"Miller NE, Clifton-Bligh P, Nestel PJ, Whyte HM. Controlled clinical trial of a new bile acid-sequestering resin, colestipol, in the treatment of hypercholesterolaemia. Medical Journal of Australia 1: 1223\u20131227, 1973","journal-title":"Medical Journal of Australia"},{"key":"BF03259858_CR123","first-page":"68s","volume":"58","author":"KS Moghissi","year":"1981","unstructured":"Moghissi KS. Risks and benefits of nutritional supplements during pregnancy. Obstetrics and Gynecology 58 (Suppl.): 68s\u201378s, 1981","journal-title":"Obstetrics and Gynecology"},{"key":"BF03259858_CR124","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/0041-008X(73)90220-2","volume":"24","author":"JA Molello","year":"1973","unstructured":"Molello JA, Gerbig CC, Robinson VB. Toxicity of [4,4\u2032-(isopropylidenedithio) bis(2,6-di-t-butylphenol)] in mice, rats, dogs and monkeys: demonstration of a species-specific phenomenon. Toxicology and Applied Pharmacology 24: 590\u2013593, 1973","journal-title":"Toxicology and Applied Pharmacology"},{"key":"BF03259858_CR125","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/j.1552-4604.1974.tb02330.x","volume":"14","author":"DT Nash","year":"1974","unstructured":"Nash DT. Safety and efficacy of probucol during one year of administration. Journal of Clinical Pharmacology 14: 470\u2013475, 1974","journal-title":"Journal of Clinical Pharmacology"},{"key":"BF03259858_CR126","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/ajr.122.2.333","volume":"122","author":"JA Nelson","year":"1974","unstructured":"Nelson JA. Effect of cholestyramine on telepaque oral cholecystography. American Journal Roentgenology Radium Therapy and Nuclear Medicine 122: 333\u2013334, 1974","journal-title":"American Journal Roentgenology Radium Therapy and Nuclear Medicine"},{"key":"BF03259858_CR127","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.1969.03160100047012","volume":"208","author":"RC Northcutt","year":"1969","unstructured":"Northcutt RC, Stiel JN, Hollifield JW, Stant Jr EG. The influence of cholestyramine on thyroxin absorption. Journal of the American Medical Association 208: 1857\u20131861, 1969","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR128","first-page":"345","volume":"92","author":"ER Nye","year":"1980","unstructured":"Nye ER, Sutherland WHF, Temple WA. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. New Zealand Medical Journal 92: 345\u2013349, 1980","journal-title":"New Zealand Medical Journal"},{"key":"BF03259858_CR129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(63)91025-0","volume":"1","author":"MF Oliver","year":"1963","unstructured":"Oliver MF, Roberts SD, Hayes D, Pantridge JF, Suzman MM, et al. Effect of atromid and ethylchlorphenoxyisobutyrate on anticoagulant requirements. Lancet 1: 143\u2013144, 1963","journal-title":"Lancet"},{"key":"BF03259858_CR130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(83)90588-3","volume":"2","author":"AG Olsson","year":"1983","unstructured":"Olsson AG, Carlson LA, Anggard E, Ciabattioni G. Prostaglandin production augmented in the short term by nicotinic acid. Lancet 2: 565\u2013567, 1983","journal-title":"Lancet"},{"issue":"2","key":"BF03259858_CR131","first-page":"28","volume":"69","author":"AG Olsson","year":"1976","unstructured":"Olsson AG, Rossner S, Walldius G, Carlson LA. Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinemia. Proceedings of the Royal Society of Medicine 69 (Suppl. 2): 28\u201331, 1976","journal-title":"Proceedings of the Royal Society of Medicine"},{"key":"BF03259858_CR132","first-page":"309","volume":"27","author":"RA O\u2019Reilly","year":"1972","unstructured":"O\u2019Reilly RA, Sahud MA, Robinson AJ. Studies on the interaction of warfarin and clofibrate in man. Thrombosis et Diathesis Haemorrhagica 27: 309\u2013318, 1972","journal-title":"Thrombosis et Diathesis Haemorrhagica"},{"key":"BF03259858_CR133","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM196201112660205","volume":"266","author":"JC Owens","year":"1962","unstructured":"Owens JC, Neely WB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. New England Journal of Medicine 266: 76\u201379, 1962","journal-title":"New England Journal of Medicine"},{"key":"BF03259858_CR134","first-page":"424","volume":"91","author":"RH Palmer","year":"1978","unstructured":"Palmer RH. Prevalence of gallstones in hyperlipidemia and incidence during treatment with clofibrate and\/or cholestyramine. Transactions of the Association of American Physicians 91: 424\u2013432, 1978","journal-title":"Transactions of the Association of American Physicians"},{"key":"BF03259858_CR135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.1961.63040020032017a","volume":"175","author":"WO Pardue","year":"1961","unstructured":"Pardue WO. Severe liver dysfunction during nicotinic acid therapy. Journal of the American Medical Association 175: 137\u2013138, 1961","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR136","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/000992288102001011","volume":"20","author":"PH Parker","year":"1981","unstructured":"Parker PH, Ghishan FK, Shanks D, Greene HL. Eosinophilia associated with cholestyramine. Clinical Pediatrics 20: 675\u2013676, 1981","journal-title":"Clinical Pediatrics"},{"key":"BF03259858_CR137","first-page":"85","volume":"107","author":"WB Parsons","year":"1961","unstructured":"Parsons WB. Studies on nicotinic acid used in hypercholesterolemia: changes in hepatic function, carbohydrate tolerance and uric acid metabolism. Archives of Internal Medicine 107: 85\u201399, 1961","journal-title":"Archives of Internal Medicine"},{"key":"BF03259858_CR138","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0002-8703(78)90088-1","volume":"96","author":"WB Parsons","year":"1978","unstructured":"Parsons WB. Effect of probucol in hyperlipidemic patients during two years of administration. American Heart Journal 96: 213\u2013217, 1978","journal-title":"American Heart Journal"},{"key":"BF03259858_CR139","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jama.1957.02980210030009","volume":"165","author":"WB Parsons Jr","year":"1957","unstructured":"Parsons Jr WB, Flinn JH. Reduction in elevated blood cholesterol levels by large doses of nicotinic acid: preliminary report. Journal of the American Medical Association 165: 234\u2013238, 1957","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00007611-198302000-00023","volume":"76","author":"DJ Patterson","year":"1983","unstructured":"Patterson DJ, Dew EW, Gyorkey F, Graham DY. Niacin hepatitis. Southern Medical Journal 76: 239\u2013241, 1983","journal-title":"Southern Medical Journal"},{"key":"BF03259858_CR141","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(75)90613-3","volume":"2","author":"AM Pierides","year":"1975","unstructured":"Pierides AM, Alvarez-Ude F, Kerr DNS, Skillen AW. Clofibrate induced muscle damage in patients with chronic renal failure. Lancet 2: 1279\u20131282, 1975","journal-title":"Lancet"},{"key":"BF03259858_CR142","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.1981.03310440039023","volume":"245","author":"RE Pieroni","year":"1981","unstructured":"Pieroni RE, Fisher JG. Use of cholestyramine resin in digitoxin toxicity. Journal of the American Medical Association 245: 1939\u20131940, 1981","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR143","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1185\/03007997309111689","volume":"1","author":"AA Polachek","year":"1973","unstructured":"Polachek AA, Katz HM, Sack J, Selig J, Littman ML. Probucol in the long-term treatment of hypercholesterolaemia. Current Medical Research and Opinion 1: 323\u2013330, 1973","journal-title":"Current Medical Research and Opinion"},{"key":"BF03259858_CR144","first-page":"332","volume":"61","author":"JR Poley","year":"1978","unstructured":"Poley JR. Cholestyramine and intestinal obstruction. Correspondence. Pediatrics 61: 332, 1978","journal-title":"Correspondence. Pediatrics"},{"key":"BF03259858_CR145","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0022-3476(77)80589-1","volume":"90","author":"WA Primack","year":"1977","unstructured":"Primack WA, Gartner LM, McGurk HE, Spitzer A. Hypernatremia associated with cholestyramine therapy. Journal of Pediatrics 90: 1024\u20131025, 1977","journal-title":"Journal of Pediatrics"},{"key":"BF03259858_CR146","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/j.1552-4604.1974.tb02315.x","volume":"14","author":"JP Rado","year":"1974","unstructured":"Rado JP, Szende L. Inhibition of clofibrate-induced antidiuresis by glybenclamide in patients with pituitary diabetes insipidus. Journal of Clinical Pharmacology 14: 290\u2013295, 1974","journal-title":"Journal of Clinical Pharmacology"},{"key":"BF03259858_CR147","first-page":"64","volume":"64","author":"EA Ramirez","year":"1972","unstructured":"Ramirez EA, Garcia Pont PH, Norat FA. A 5-year double blind controlled clinical trial of D-thyroxine on euthyroid coronary subjects: final report. Boletin \u2014 Asociacion Medica de Puerto Rico 64: 64\u201373, 1972","journal-title":"Boletin \u2014 Asociacion Medica de Puerto Rico"},{"key":"BF03259858_CR148","first-page":"63","volume":"40","author":"DJ Reinhardt III","year":"1968","unstructured":"Reinhardt III DJ. The use of dextro-thyroxine (Choloxin) in cardiovascular disease: report of a clinical study. Delaware Medical Journal 40: 63\u201367, 1968","journal-title":"Delaware Medical Journal"},{"key":"BF03259858_CR149","first-page":"414","volume-title":"Probucol. In Martindale, the extra pharmacopoeia","year":"1982","unstructured":"Reynolds JEF (Ed.). Probucol. In Martindale, the extra pharmacopoeia, 28th ed., p. 414, The Pharmaceutical Press, London, 1982","edition":"28th"},{"key":"BF03259858_CR150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0021-9150(80)90229-4","volume":"36","author":"WF Riesen","year":"1980","unstructured":"Riesen WF, Keller M, Mordasini R. Probucol in hypercholesterolemia. Atherosclerosis 36: 201\u2013207, 1980","journal-title":"Atherosclerosis"},{"key":"BF03259858_CR151","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.1959.63010170008010c","volume":"170","author":"AU Rivin","year":"1959","unstructured":"Rivin AU. Jaundice occurring during nicotinic acid therapy for hypercholesterolemia. Journal of the American Medical Association 170: 2088\u20132089, 1959","journal-title":"Journal of the American Medical Association"},{"key":"BF03259858_CR152","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.0954-6820.1972.tb04780.x","volume":"192","author":"L Runeberg","year":"1972","unstructured":"Runeberg L, Miettinen TA, Nikkila EA. Effect of cholestyramine on mineral excretion in man. Acta Medica Scandinavica 192: 71\u201376, 1972","journal-title":"Acta Medica Scandinavica"},{"key":"BF03259858_CR153","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cpt197517183","volume":"17","author":"JR Ryan","year":"1975","unstructured":"Ryan JR, Jain AK, McMahon FG. Long-term treatment of hypercholesterolemia with colestipol hydrochloride. Clinical Pharmacology and Therapeutics 17: 83\u201387, 1975","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259858_CR154","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3181\/00379727-147-38419","volume":"147","author":"BA Sachs","year":"1974","unstructured":"Sachs BA, Wolfman L. Colestipol therapy of hyperlipidemia in man. Proceedings of the Society for Experimental Biology and Medicine 147: 694\u2013697, 1974","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"BF03259858_CR155","doi-asserted-by":"crossref","first-page":"2s","DOI":"10.1378\/chest.89.2_Supplement.2S","volume":"89","author":"DL Sackett","year":"1986","unstructured":"Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 89 (Suppl.): 2s\u20133s, 1986","journal-title":"Chest"},{"issue":"5A","key":"BF03259858_CR156","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0002-9343(18)30279-1","volume":"74","author":"P Samuel","year":"1983","unstructured":"Samuel P. Effects of gemfibrozil on serum lipids. American Journal of Medicine 74 (Suppl. 5A): 23\u201327, 1983","journal-title":"American Journal of Medicine"},{"key":"BF03259858_CR157","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJM197909133011108","volume":"301","author":"P Samuel","year":"1979","unstructured":"Samuel P. Treatment of hypercholesterolaemia with neomycin: a time for reappraisal. New England Journal of Medicine 301: 595\u2013597, 1979","journal-title":"New England Journal of Medicine"},{"key":"BF03259858_CR158","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/01.CIR.35.5.938","volume":"35","author":"P Samuel","year":"1967","unstructured":"Samuel P, Holtzman CM, Goldstein J. Long-term reduction of serum cholesterol levels of patients with atherosclerosis by small doses of neomycin. Circulation 35: 938\u2013945, 1967","journal-title":"Circulation"},{"key":"BF03259858_CR159","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.CIR.41.1.109","volume":"41","author":"P Samuel","year":"1970","unstructured":"Samuel P, Holtzman CM, Meilman E, Sekowski I. Reduction of serum cholesterol and triglyceride levels by the combined administration of neomycin and clofibrate. Circulation 41: 109\u2013114, 1970","journal-title":"Circulation"},{"key":"BF03259858_CR160","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.0954-6820.1976.tb06712.x","volume":"199","author":"RWB Schade","year":"1976","unstructured":"Schade RWB, van\u2019t Laar A, Majoor CLH, Jansen AP. A comparative study of the effects of cholestyramine and neomycin in the treatment of type II hyperlipoproteinaemia. Acta Medica Scandinavica 199: 175\u2013180, 1976","journal-title":"Acta Medica Scandinavica"},{"key":"BF03259858_CR161","first-page":"351","volume":"17","author":"P Schwandt","year":"1979","unstructured":"Schwandt P. Drug interactions and side effects of hypolipidemic drugs. International Journal of Clinical Pharmacology and Biopharmacy 17: 351\u2013356, 1979","journal-title":"International Journal of Clinical Pharmacology and Biopharmacy"},{"key":"BF03259858_CR162","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cpt196781part170","volume":"8","author":"JJ Schrogie","year":"1967","unstructured":"Schrogie JJ, Soloman HM. The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate, and norethandrolone. Clinical Pharmacology and Therapeutics 8: 70\u201377, 1967","journal-title":"II. The effect of D-thyroxine, clofibrate, and norethandrolone. Clinical Pharmacology and Therapeutics"},{"key":"BF03259858_CR163","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0002-9149(72)90053-7","volume":"30","author":"I Sekowski","year":"1972","unstructured":"Sekowski I, Samuel P. Clofibrate-induced acute muscular syndrome. American Journal of Cardiology 30: 572\u2013574, 1972","journal-title":"American Journal of Cardiology"},{"key":"BF03259858_CR164","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0140-6736(74)91404-4","volume":"2","author":"K Sigroth","year":"1974","unstructured":"Sigroth K. Effect of clonidine on nicotinic acid flushing. Correspondence. Lancet 2: 58, 1974","journal-title":"Correspondence. Lancet"},{"key":"BF03259858_CR165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/bmj.2.5701.86","volume":"2","author":"AF Smith","year":"1970","unstructured":"Smith AF, Macfie WG, Oliver MF. Clofibrate, serum enzymes, and muscle pain. British Medical Journal 2: 86\u201388, 1970","journal-title":"British Medical Journal"},{"key":"BF03259858_CR166","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00000542-198108000-00011","volume":"55","author":"MD Sokoll","year":"1981","unstructured":"Sokoll MD, Gergis SD. Antibiotics and neuromuscular function. Anesthesiology 55: 148\u2013159, 1981","journal-title":"Anesthesiology"},{"key":"BF03259858_CR167","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0002-8703(72)90148-2","volume":"83","author":"HM Soloman","year":"1972","unstructured":"Soloman HM, Abrams WB. Interaction between digitoxin and other drugs in man. American Heart Journal 83: 277\u2013280, 1972","journal-title":"American Heart Journal"},{"key":"BF03259858_CR168","first-page":"2002","volume":"73","author":"RB Solomon","year":"1973","unstructured":"Solomon RB, Rosner F. Massive hemorrhage and death during treatment with clofibrate and warfarin. New York State Journal of Medicine 73: 2002\u20132003, 1973","journal-title":"New York State Journal of Medicine"},{"key":"BF03259858_CR169","first-page":"400","volume":"10","author":"P Starr","year":"1970","unstructured":"Starr P. Cardiac tolerance for cholesteropenic doses of dextrothyroxine. Journal of Clinical Pharmacology 10: 400\u2013407, 1970","journal-title":"Journal of Clinical Pharmacology"},{"key":"BF03259858_CR170","first-page":"1252","volume":"49","author":"EA Stein","year":"1975","unstructured":"Stein EA, Heimann KW. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia. South African Medical Journal 49: 1252\u20131256, 1975","journal-title":"South African Medical Journal"},{"key":"BF03259858_CR171","first-page":"1085","volume-title":"Metabolic effects of nicotinic acid and its derivatives","author":"N Svedmyr","year":"1971","unstructured":"Svedmyr N, Harthon L, Lundholm L. Dose response relationship between concentration of free nicotinic acid concentration of plasma and some metabolic and circulatory effects after administration of nicotinic acid and pentaepythritol tetranicotinate in man. In Gey & Carlson (Eds) Metabolic effects of nicotinic acid and its derivatives, p. 1085\u20131098, Hans Huber, Bern, 1971"},{"key":"BF03259858_CR172","first-page":"22","volume":"10","author":"RE Tedeschi","year":"1982","unstructured":"Tedeschi RE, Martz BL, Taylor HA, Cerimele BJ. Safety and effectiveness of probucol as a cholesterol lowering agent. Artery 10: 22\u201334, 1982","journal-title":"Artery"},{"key":"BF03259858_CR173","first-page":"70","volume":"78","author":"FB Thomas","year":"1971","unstructured":"Thomas FB, McCullough FS, Greenberger NJ. Inhibition of the intestinal absorption of inorganic and hemoglobin iron by cholestyramine. Journal of Laboratory and Clinical Medicine 78: 70\u201380, 1971","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"BF03259858_CR174","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF02232300","volume":"17","author":"FB Thomas","year":"1972","unstructured":"Thomas FB, Salsburey D, Greenberger NJ. Inhibition of iron absorption by cholestyramine: demonstration of diminished iron stores following prolonged administration. American Journal of Digestive Diseases 17: 263\u2013269, 1972","journal-title":"American Journal of Digestive Diseases"},{"key":"BF03259858_CR175","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/BF01073335","volume":"18","author":"WG Thompson","year":"1973","unstructured":"Thompson WG. Effect of cholestyramine on absorption of 3H digoxin in rats. American Journal of Digestive Diseases 18: 851\u2013856, 1973","journal-title":"American Journal of Digestive Diseases"},{"key":"BF03259858_CR176","first-page":"607","volume":"119","author":"TY Ti","year":"1978","unstructured":"Ti TY, Giles HG, Sellers EM. Probable interaction of loperamide and cholestyramine. Canadian Medical Association Journal 119: 607\u2013608, 1978","journal-title":"Canadian Medical Association Journal"},{"key":"BF03259858_CR177","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.0954-6820.1982.tb08534.x","volume":"668","author":"I Torstila","year":"1982","unstructured":"Torstila I, Kaukola S, Manninen V, Virtamo J, Malkonen M. Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia. Acta Medica Scandinavica 668 (Suppl.): 123\u2013129, 1982","journal-title":"Acta Medica Scandinavica"},{"key":"BF03259858_CR178","first-page":"20","volume":"77","author":"JA Udall","year":"1970","unstructured":"Udall JA. Drug interference with warfarin therapy. Clinical Medicine 77: 20\u201325, 1970","journal-title":"Clinical Medicine"},{"key":"BF03259858_CR179","first-page":"1891","volume":"26","author":"RJ Bever van","year":"1976","unstructured":"van Bever RJ, Duchateau AMJA, Pluym BFM, Merkus FWHM. The effect of colestipol on digitoxin plasma levels. Arzneimittel-Forschung 26: 1891\u20131893, 1976","journal-title":"Arzneimittel-Forschung"},{"key":"BF03259858_CR180","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archinte.1982.00340170077016","volume":"142","author":"TJ Vecchio","year":"1982","unstructured":"Vecchio TJ, Linden CV, O\u2019Connell MJ, Heilman J. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia. Archives of Internal Medicine 142: 721\u2013723, 1982","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"BF03259858_CR181","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/00359157760690S208","volume":"69","author":"B Vessby","year":"1976","unstructured":"Vessby B, Lithell H, Boberg J, Hellsing K, Werner I. Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia: a placebo controlled cross-over trial. Proceedings of the Royal Society of Medicine 69 (Suppl. 2): 32\u201337, 1976","journal-title":"Proceedings of the Royal Society of Medicine"},{"key":"BF03259858_CR182","first-page":"22","volume":"2","author":"J Virtamo","year":"1984","unstructured":"Virtamo J, Manninen V, Malkonen M. A placebo-controlled, rising-dose, double-blind trial with gemfibrozil in dieting patients with primary hyperlipoproteinemia. Vascular Medicine 2: 22\u201327, 1984","journal-title":"Vascular Medicine"},{"key":"BF03259858_CR183","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/j.1552-4604.1979.tb02464.x","volume":"19","author":"WM Wardell","year":"1979","unstructured":"Wardell WM, Tsianco MC, Anavekar SN, Davis HT. Postmarketing surveillance of new drugs: I. Review of objectives and methodology. Journal of Clinical Pharmacology 19: 85\u201394, 1979","journal-title":"Review of objectives and methodology. Journal of Clinical Pharmacology"},{"key":"BF03259858_CR184","first-page":"631","volume":"49","author":"GS Watermeyer","year":"1975","unstructured":"Watermeyer GS, Mann JI, Truswell AS, Levy I. Type IIa hyperlipoproteinaemia: an evaluation of four therapeutic regimens. South African Medical Journal 49: 631\u2013634, 1975","journal-title":"South African Medical Journal"},{"key":"BF03259858_CR185","first-page":"82","volume":"51","author":"RJ West","year":"1975","unstructured":"West RJ, Fosbrooke AS, Lloyd JK. Treatment of children with familial hypercholesterolemia. Postgraduate Medical Journal 51 (Suppl.): 82\u201387, 1975","journal-title":"Postgraduate Medical Journal"},{"key":"BF03259858_CR186","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/adc.48.5.370","volume":"48","author":"RJ West","year":"1973","unstructured":"West RJ, Lloyd JK. Use of cholestyramine in treatment of children with familial hypercholesterolemia. Archives of Disease in Children 48: 370\u2013374, 1973","journal-title":"Archives of Disease in Children"}],"container-title":["Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03259858.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03259858\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03259858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T22:50:33Z","timestamp":1745362233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03259858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,2]]},"references-count":186,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1987,2]]}},"alternative-id":["BF03259858"],"URL":"https:\/\/doi.org\/10.1007\/bf03259858","relation":{},"ISSN":["0112-5966"],"issn-type":[{"value":"0112-5966","type":"print"}],"subject":[],"published":{"date-parts":[[1987,2]]}}}